Group 1 - The core viewpoint is that Hong Kong's innovative drug concept stocks have strengthened, with companies like Innovent Biologics, BeiGene, and CanSino Biologics rising over 2% [1] - The Hong Kong innovative drug-related ETFs have increased by approximately 2% due to the rise of heavy-weight stocks [1] Group 2 - The current prices and changes of relevant ETFs are as follows: Hong Kong Innovative Drug ETF (code: 520880) is priced at 1.230 with an increase of 0.023 (1.91%); Hong Kong Innovative Drug Select ETF (code: 520690) is priced at 0.996 with an increase of 0.020 (2.05%) [2] - Analysts indicate that multinational pharmaceutical companies have significantly increased their procurement of innovative drug patents in China this year, with the procurement amount from January to May nearing the total for the entire year of 2024, demonstrating the competitiveness of China's innovative drugs in the international market [2] - The trend of large multinational pharmaceutical companies accelerating the procurement of innovative drug patents from China is expected to continue in the medium to long term [2]
港股创新药概念股走强，相关ETF涨约2%
Mei Ri Jing Ji Xin Wen·2025-08-05 02:12